文献速递皮肤肿瘤

Adcitmer®:靶向CD56的MMAE偶联抗体在Merkel细胞癌中的潜在治疗作用

Adcitmer® , a new CD56-targeting monomethyl auristatin E-conjugated antibody, is a potential therapeutic approach in Merkel cell carcinoma.
PubMed 文献 · Br J Dermatol · 2021-11-02

Merkel细胞癌(MCC)侵袭性强且肿瘤细胞常表达CD56。本研究在90例MCC组织芯片中评估CD56表达,并构建靶向CD56的抗体药物偶联物Adcitmer®,在体外MCC细胞系及小鼠异种移植模型中验证其细胞毒性和抑瘤效果。结果显示Adcitmer®可显著抑制肿瘤生长,提示其可作为MCC的候选治疗策略。

要点

  • CD56在66%的MCC肿瘤中表达,支持其作为治疗靶点。
  • Adcitmer®在体外对MCC细胞系显示CD56介导的细胞毒性。
  • Adcitmer®在小鼠MCC模型中显著减少肿瘤生长。

核心结论

  • Adcitmer®在MCC临床前模型中显示治疗潜力,值得进一步评估作为替代或联合免疫检查点抑制剂的方案。

研究设计与样本

  • 在90例MCC组织芯片中免疫组化评估CD56表达,并检测MCC细胞系。
  • 将靶向CD56抗体与单甲基澳瑞他汀E(MMAE)经McSAF Inside®生物偶联制备Adcitmer®,用疏水相互作用色谱表征其化学性质与均一性。
  • 在体外MCC细胞系和小鼠MCC异种移植模型中评估Adcitmer®的细胞毒性和抑瘤效果。

主要发现

  • CD56在66%的MCC肿瘤中表达。
  • 未偶联的CD56靶向抗体在MCC细胞系中显示特异性结合和内化。
  • Adcitmer®在体外MCC细胞系中显示CD56介导的细胞毒性。
  • Adcitmer®在小鼠MCC模型中显著减少肿瘤生长。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Merkel cell carcinoma (MCC) is an aggressive skin cancer, whose tumour cells often express CD56. While immune checkpoint inhibitors constitute a major advance for treating patients with MCC with advanced disease, new therapeutic options are still urgently required. OBJECTIVES: To produce and evaluate the therapeutic performance of a new antibody-drug conjugate (Adcitmer® ) targeting CD56 in preclinical models of MCC. METHODS: CD56 expression was evaluated in a MCC cohort (immunohistochemistry on a tissue microarray of 90 tumour samples) and MCC cell lines. Interaction of an unconjugated CD56-targeting antibody with CD56+ MCC cell lines was investigated by immunohistochemistry and imaging flow cytometry. Adcitmer® product was generated by the bioconjugation of CD56-targeting antibody to a cytotoxic drug (monomethyl auristatin E) using the McSAF Inside® bioconjugation process. The chemical properties and homogeneity of Adcitmer® were characterized by hydrophobic interaction chromatography. Adcitmer® cytotoxicity was evaluated in vitro and in an MCC xenograft mice model. RESULTS: Similar to previous reports, CD56 was expressed by 66% of MCC tumours in our cohort, confirming its relevance as a therapeutic target. Specific binding and internalization of the unconjugated CD56-targeting antibody was validated in MCC cell lines. The high homogeneity of the newly generated Adcitmer® was confirmed by hydrophobic interaction chromatography. The CD56-mediated cytotoxicity of Adcitmer® was demonstrated in vitro in MCC cell lines. Moreover, Adcitmer® significantly reduced tumour growth in a MCC mouse model. CONCLUSIONS: Our study suggests that Adcitmer® should be further assessed as a therapeutic option in patients with MCC, as an alternative therapy or combined with immune checkpoint inhibitors.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Esnault C, Leblond V, Martin C, et al. Adcitmer® , a new CD56-targeting monomethyl auristatin E-conjugated antibody, is a potential therapeutic approach in Merkel cell carcinoma. Br J Dermatol. 2021. PMID: 34582565. doi:10.1111/bjd.20770

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。